Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Therapeutic Use
  • Acronyms T-Force GREEN
  • Sponsors Neurocrine Biosciences

    • Most Recent Events

    • 09 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 03 Aug 2017 Primary endpoint Severity of tic symptoms assessed by Yale Global Tic Severity Scale YGTSS time frame Week 6has not been met.
    • 09 May 2017 According to a Neurocrine Biosciences media release, data from the study is anticipated in May 2017.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top